MEK Inhibitor Treatment Promotes Retinal Ganglion Cell Preservation without Preventing Retrobulbar Demyelination in Neurofibromatosis Mice
Creator
Steven Stasheff; Francisco Nadal-Nicolas; Wei Li; Miriam Bornhorst; Yuan Zhu
Affiliation
(SS) Neuroscience & Gilbert NF Inst, Children's National Health Sys; National Eye Institute, Washington, District of Columbia; (FN) (WL) (YZ) Retinal Neurophysiology Section, National Eye Institute, Bethesda, Maryland; (MB) (YZ) Gilbert Neurofibromatosis Institute, Children's National Health System, Washington, District of Columbia
To better understand the disparity frequently seen between optic pathway glioma (OPG) characteristics and visual loss among young children with neurofibromatosis type 1 (NF1), we extend our previous findings of anatomic, physiologic, and behavioral abnormalities in an established animal model. We now report differential effects of treatment targeting the MAPK/ERK cellular pathway: 1) preserving retinal ganglion cell (RGC) number, and yet 2) failing to ameliorate demyelination of the retrobulbar optic nerve.
Date
2019-03
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2019 North American Neuro-Ophthalmology Society Annual Meeting
